FDA Approves Exdensur for Severe Asthma

MONDAY, Dec. 22, 2025 -- The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged 12 years and...